GUTS vs DBVT vs NVAX vs NVO

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -100. 0% for Fractyl Health, Inc. Common Stock (GUTS). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Fractyl Health, Inc. Common Stock (GUTS) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Novo Nordisk A/S at 12. 6x.

Over the past 5 years, Novo Nordisk A/S (NVO) delivered a total return of +36.

4%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: NVO returned +99. 6% versus GUTS's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Fractyl Health, Inc. Common Stock's 2. 15β — meaning GUTS is approximately 71% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 7% for Fractyl Health, Inc. Common Stock — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -100. 0% for Fractyl Health, Inc. Common Stock (GUTS). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, NVO leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for GUTS: 568.

4% to $5. 00.

In this comparison, NVO (4.

0% yield) pays a dividend. GUTS, DBVT, NVAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novo Nordisk A/S (NVO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (4.

0% yield). Fractyl Health, Inc. Common Stock (GUTS) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVO: +99. 6%, GUTS: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GUTS is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; NVAX is a small-cap high-growth stock; NVO is a large-cap deep-value stock. NVO pays a dividend while GUTS, DBVT, NVAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.